ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,675.12
0.64%
Dow Jones
41,841.63
0.85%
US Dollar vs MXN
19.98203
0.11%
Brent Oil
71.005
0.49%
Bitcoin
83,145.44
-1.09%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Adaptimmune Therapeutics PLC (ADAP)

  7. Adaptimmune Therapeutics PLC (ADAP) Noticias

ADAP

Adaptimmune Therapeutics (ADAP)

Adaptimmune Therapeutics PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ADAP
FechaHoraFuenteTítuloSímboloCompañía
20/02/202516:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADAPAdaptimmune Therapeutics PLC
14/02/202508:31Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ADAPAdaptimmune Therapeutics PLC
17/01/202514:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ADAPAdaptimmune Therapeutics PLC
19/12/202406:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADAPAdaptimmune Therapeutics PLC
13/11/202415:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADAPAdaptimmune Therapeutics PLC
12/08/202404:47IH Market NewsU.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices ClimbNASDAQ:ADAPAdaptimmune Therapeutics PLC
01/08/202419:20Business WireAdaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid TumorNASDAQ:ADAPAdaptimmune Therapeutics PLC
30/11/202315:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ADAPAdaptimmune Therapeutics PLC
10/08/202315:05Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ADAPAdaptimmune Therapeutics PLC
29/06/202315:54Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ADAPAdaptimmune Therapeutics PLC
29/06/202315:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ADAPAdaptimmune Therapeutics PLC
01/06/202315:49Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ADAPAdaptimmune Therapeutics PLC
22/05/202306:02Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:ADAPAdaptimmune Therapeutics PLC
12/05/202315:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ADAPAdaptimmune Therapeutics PLC
21/04/202305:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ADAPAdaptimmune Therapeutics PLC
13/04/202307:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ADAPAdaptimmune Therapeutics PLC
11/04/202317:33Dow Jones NewsADRs End Higher, Adaptimmune Therapeutics and Alibaba Trade ActivelyNASDAQ:ADAPAdaptimmune Therapeutics PLC
05/04/202315:41Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:ADAPAdaptimmune Therapeutics PLC
03/04/202307:01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ADAPAdaptimmune Therapeutics PLC
14/02/202315:20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ADAPAdaptimmune Therapeutics PLC
18/11/202212:55TipRanksAdaptimmune Therapeutics (ADAP) Gets a Buy from Mizuho SecuritiesNASDAQ:ADAPAdaptimmune Therapeutics PLC
09/11/202222:35TipRanksSVB Securities Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
26/10/202216:55TipRanksMizuho Securities Keeps Their Hold Rating on Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
09/09/202217:02Dow Jones NewsADRs End Higher, Argo Blockchain and Adaptimmune Therapeutics Trade ActivelyNASDAQ:ADAPAdaptimmune Therapeutics PLC
05/09/202218:05TipRanksMizuho Securities Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
05/08/202210:35TipRanksAdaptimmune Therapeutics (ADAP) Receives a Buy from JonesTradingNASDAQ:ADAPAdaptimmune Therapeutics PLC
04/08/202212:15TipRanksAdaptimmune Therapeutics (ADAP) Gets a Hold Rating from Mizuho SecuritiesNASDAQ:ADAPAdaptimmune Therapeutics PLC
01/07/202216:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ADAPAdaptimmune Therapeutics PLC
16/05/202217:25TipRanksMizuho Securities Remains a Hold on Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
16/05/202216:00GlobeNewswire Inc.Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCTNASDAQ:ADAPAdaptimmune Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ADAP

Su Consulta Reciente

LSE
SKG
Smurfit Kappa
LATK
KAUUSDT
Kauri
EU
MC
Lvmh Moet Hennessy Louis...
LSE
IDS
International Distributi...
LSE
RWI
Renewi
LATK
BRISEUSDT
Bitgert
LSE
AGL
Angle
LATK
METETH
Metronome
LSE
0KJF
Apranga Apb
NYSE
CFXA
Colfax
USOTC
BLGO
BioLargo (QX)
TSX
BABY
Else Nutrition
NASDAQ
ABMCYXX
Jpmorgan Chase Financial...
LSE
HAWK
Nighthawk Energy
NASDAQ
CAKMX
Canoe Global Income Fund...
TSXV
GRZ
Gold Reserve
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios